 |
|
|
| |
Impact of Baseline HCV RNA Levels as Assessed by 2 Different Assays on the Efficacy of 8-Week Glecaprevir/Pibrentasvir
in Patients With HCV GT1-6 Infection
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Heiner Wedemeyer1, Shyam Kotti lil2, Douglas E Dylla3, Marc Bourliere4, Christoph Sarrazin5, James M Levin6, Armen Asatryan3, Yiran B Hu3, Mitchell L Shiff man7
1Medizinische Hochschule Hannover, Hannover, Germany; 2Insti tute of Human Virology, University of Maryland School of Medicine, Balti more, Maryland, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Hôpital Saint Joseph, Marseilles, France;
5JW Goethe University Hospital, Frankfurt, Germany and St. Josefs-Hospital Wiesbaden, Wiesbaden, Germany; 6SSM Health Dean Medical Group, Madison, Wisconsin, United States; 7Liver Insti tute of Virginia, Bon Secours Health System, Richmond, Virginia, United States
|
| |
|
|
|
|
|
